Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 1/20 | 0.35 |
| ▸ | PTDSS1 | P48651 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4705746 | 0.86 | PDE4B (0.72) | PDE4BTP53SMN1; SMN2KDR | |
| SCHEMBL4708777 | 0.86 | PDE4B (0.62) | PDE4BSMN1; SMN2ALPLALPIALPG | |
| SCHEMBL4706104 | 0.85 | PDE4B (0.68) | PDE4BSMN1; SMN2 | |
| SCHEMBL4707984 | 0.84 | PDE4B (0.55) | PDE4BSMN1; SMN2 | |
| SCHEMBL4706107 | 0.83 | PDE4B (0.70) | PDE4BTP53SMN1; SMN2KDR | |
| SCHEMBL4705775 | 0.82 | PDE4B (0.58) | PDE4BTP53 | |
| SCHEMBL6169312 | 0.81 | PDE4B (0.65) | PDE4BTP53SMN1; SMN2 | |
| SCHEMBL4709794 | 0.81 | PDE4B (0.57) | PDE4BSMN1; SMN2 | |
| SCHEMBL4706986 | 0.80 | PDE4B (0.57) | PDE4BSMN1; SMN2 | |
| SCHEMBL4706532 | 0.80 | PDE4B (0.57) | PDE4BSMN1; SMN2ALPLALPIALPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459453-B2 | Pyridazin-3(2H)-one derivatives as PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-12-02 | — | — | US | claimed |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-03-09 | — | — | US | claimed |
| EP-1503992-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-02-09 | — | — | EP | claimed |
| WO-2003097613-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL PRODESFARMA SA (ES) | 2003-11-27 | — | — | WO | claimed |
| US-7459453-B2 | Pyridazin-3(2H)-one derivatives as PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-12-02 | — | — | US | disclosed |
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | DAL PIAZ VITTORIO | 2008-10-30 | — | — | US | disclosed |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-03-09 | — | — | US | disclosed |
| EP-1503992-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003097613-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL PRODESFARMA SA (ES) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE3A, PDE4B | PDE4B 3/4885TP53 4836/4885MET 4713/4885 |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | PDE4B 3/4885TP53 4836/4885MET 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.